Aldeyra Therapeutics to Participate in Upcoming Conferences
11/09/2021 - 04:05 PM
LEXINGTON, Mass. --(BUSINESS WIRE)--
Aldeyra Therapeutics, Inc. Todd C. Brady , M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:
Berenberg US CEO Conference
Wednesday, November 10, 2021
10:00 a.m. ET
https://ir.aldeyra.com/ . The recorded webcast will be archived and available for 90 days.
Eyecelerator@AAO 2021
Format: Retina Showcase Presentation
Thursday, November 11, 2021
1:05 p.m. CT (2:05 p.m. ET )
Jefferies London Healthcare Conference
8:00 a.m. GMT (3:00 a.m. ET ) Thursday, November 18, 2021
https://ir.aldeyra.com/ . The recorded webcast will be archived and available for 90 days.
Ophthalmology Day at BTIG
Format: Analyst-Hosted Fireside Chat
Tuesday, November 30, 2021
1:00 p.m. ET
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the Company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The Company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn , Facebook , and Twitter .
View source version on businesswire.com : https://www.businesswire.com/news/home/20211109006224/en/
Corporate Contact:
Joshua Reed
Aldeyra Therapeutics, Inc.
jreed@aldeyra.com
Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
ALDX@investorrelations.com
Source: Aldeyra Therapeutics, Inc.
ALDX Rankings
#5198 Ranked by Stock Gains
ALDX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About ALDX
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
